News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN), GlaxoSmithKline (GSK) Eyes More Deals


7/2/2012 8:17:33 AM

AstraZeneca and GlaxoSmithKline, both of which are based in the United Kingdom and have big operations in the Philadelphia region, were busy in the last few days trying to make deals to add external pieces to their pharmaceutical portfolios. Late Friday night, AstraZeneca announced that it would pay $3.4 billion to Amylin Pharmaceuticals - after Amylin is acquired by Bristol-Myers Squibb in a multi-pronged deal that amounts to about $7 billion. Basically, AstraZeneca will share expenses and profits from Amylin with Bristol-Myers Squibb on Amylin's diabetes drugs.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES